Protective efficacy of an H5/H7 trivalent inactivated vaccine produced from Re-11, Re-12, and H7-Re2 strains against challenge with different H5 and H7 viruses in chickens

• Main Authors: Xian-ying ZENG, Xiao-han CHEN, Shu-jie MA, Jiao-jiao WU, Hong-mei BAO, Shu-xin PAN, Yan-jing LIU, Guo-hua DENG, Jian-zhong SHI, Pu-cheng CHEN, Yong-ping JIANG, Yan-bing LI, Jing-lei HU, Tong LU, Sheng-gang MAO, Xing-fu GUO, Jing-li LIU, Guo-bin TIAN, Hua-lan CHEN
• Format: Article
• Language: English
• Published: Elsevier 2020-09-01
• Series: Journal of Integrative Agriculture
• Subjects: avian influenza; H5/H7 trivalent vaccine; Re-11; Re-12 and H7-Re2 strains; protective efficacy
• Online Access: http://www.sciencedirect.com/science/article/pii/S2095311920633019
• ISSN: 2095-3119

We developed an H5/H7 trivalent inactivated vaccine by using Re-11, Re-12, and H7-Re2 vaccine seed viruses, which were generated by reverse genetics and derived their HA genes from A/duck/Guizhou/S4184/2017(H5N6) (DK/GZ/S4184/17) (a clade 2.3.4.4d virus), A/chicken/Liaoning/SD007/2017(H5N1) (CK/LN/SD007/17) (a clade 2.3.2.1d virus), and A/chicken/Guangxi/SD098/2017(H7N9) (CK/GX/SD098/17), respectively. The protective efficacy of this novel vaccine and that of the recently used H5/H7 bivalent inactivated vaccine against different H5 and H7N9 viruses was evaluated in chickens. We found that the H5/H7 bivalent vaccine provided solid protection against the H7N9 virus CK/GX/SD098/17, but only 50–60% protection against different H5 viruses. In contrast, the novel H5/H7 trivalent vaccine provided complete protection against the H5 and H7 viruses tested. Our study underscores the importance of timely updating of vaccines for avian influenza control.